Reading School of Pharmacy, University of Reading, Whiteknights, Reading, UK.
Br J Pharmacol. 2012 Dec;167(8):1679-90. doi: 10.1111/j.1476-5381.2012.02129.x.
Calcitonin gene-related peptide (CGRP) is a potent vasodilator, implicated in the pathogenesis of migraine. CGRP activates a receptor complex comprising, calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). In vitro studies indicate recycling of CLR●RAMP1 is regulated by degradation of CGRP in early endosomes by endothelin-converting enzyme-1 (ECE-1). However, it is not known if ECE-1 regulates the resensitization of CGRP-induced responses in functional arterial tissue.
CLR, ECE-1a-d and RAMP1 expression in rat mesenteric artery smooth muscle cells (RMA-SMCs) and mesenteric arteries was analysed by RT-PCR and by immunofluorescence and confocal microscopy. CGRP-induced signalling in cells was examined by measuring cAMP production and ERK activation. CGRP-induced relaxation of arteries was measured by isometric wire myography. ECE-1 was inhibited using the specific inhibitor, SM-19712.
RMA-SMCs and arteries contained mRNA for CLR, ECE-1a-d and RAMP1. ECE-1 was present in early endosomes of RMA-SMCs and in the smooth muscle layer of arteries. CGRP induced endothelium-independent relaxation of arteries. ECE-1 inhibition had no effect on initial CGRP-induced responses but reduced cAMP generation in RMA-SMCs and vasodilation in mesenteric arteries responses to subsequent CGRP challenges.
ECE-1 regulated the resensitization of responses to CGRP in RMA-SMCs and mesenteric arteries. CGRP-induced relaxation did not involve endothelium-derived pathways. This is the first report of ECE-1 regulating CGRP responses in SMCs and arteries. ECE-1 inhibitors may attenuate an important vasodilatory pathway, implicated in primary headaches and may represent a new therapeutic approach for the treatment of migraine.
降钙素基因相关肽(CGRP)是一种强效的血管舒张剂,与偏头痛的发病机制有关。CGRP 激活包含降钙素受体样受体(CLR)和受体活性修饰蛋白 1(RAMP1)的受体复合物。体外研究表明,CLR●RAMP1 的循环是通过内皮素转换酶-1(ECE-1)在早期内体中降解 CGRP 来调节的。然而,目前尚不清楚 ECE-1 是否调节功能性动脉组织中 CGRP 诱导反应的重新敏化。
通过 RT-PCR 和免疫荧光及共聚焦显微镜分析大鼠肠系膜动脉平滑肌细胞(RMA-SMCs)和肠系膜动脉中 CLR、ECE-1a-d 和 RAMP1 的表达。通过测量 cAMP 产生和 ERK 激活来检测细胞中 CGRP 诱导的信号转导。通过等长线描记术测量动脉的 CGRP 诱导松弛。使用特异性抑制剂 SM-19712 抑制 ECE-1。
RMA-SMCs 和动脉含有 CLR、ECE-1a-d 和 RAMP1 的 mRNA。ECE-1 存在于 RMA-SMCs 的早期内体中和动脉的平滑肌层中。CGRP 诱导动脉的内皮非依赖性松弛。ECE-1 抑制对初始 CGRP 诱导的反应没有影响,但减少了 RMA-SMCs 中 cAMP 的产生和随后 CGRP 挑战时肠系膜动脉对血管舒张反应的作用。
ECE-1 调节了 RMA-SMCs 和肠系膜动脉对 CGRP 反应的重新敏化。CGRP 诱导的松弛不涉及内皮衍生途径。这是 ECE-1 调节平滑肌细胞和动脉中 CGRP 反应的第一项报道。ECE-1 抑制剂可能会减弱原发性头痛中涉及的重要血管舒张途径,并可能成为偏头痛治疗的新方法。